Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced the acquisition of cardiology company MyoKardia for about $13.1 billion.

Acer Therapeutics in-licensed the clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist osanetant from Sanofi. MyoKardia regained global rights to all the programs that the company had inked with Sanofi.